ViroMed Receives Approval for Diabetic Neuropathy Phase I/II Trial
SEOUL, KOREA, Mar. 6 – ViroMed Co., Ltd. (KOSDAQ: 084990) today announced that the company has received approval from the US Food and Drug Administration (FDA) to start clinical trials for diabetic neuropathy, a major complication of diabetes mellitus.
The Phase I/II clinical trial will take place at various medical centers, including Northwestern Memorial Hospital, under the guidance of Dr Douglas Losordo, Director, Feinberg Cardiovascular Research Institute.
˝The clinical trial approval of VM202-DPN allows us not only to anticipate the globalization of Korean technology and the possibility of a new worldwide drug,˝ says Dr Kim, ˝but also to look forward to an improvement in the quality of life for patients with diabetes who have no other alternatives.˝